The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.
Algorithms developed at Oak Ridge National Laboratory can greatly enhance X-ray computed tomography images of 3D-printed metal parts, resulting in more accurate, faster scans.